Migraine in Children and Adolescents

Clinical trial for children and adolescents (aged 6-17 years) with a history of migraine with and without aura.

6 - 17 years of age
Compensation Provided
About the Study
The purpose of this study is to evaluate how safe and effective the investigational drug ubrogepant is in the acute treatment of migraine in children and adolescents.
What does the study involve?
Ubrogepant is approved for the acute treatment of migraine in adults but has not been studied in children 6-17 years of age. The study will include 2 cohorts of participants - PK Cohort for children 6 to 11 years of age and the Main safety and efficacy study for children 6 to 17 years of age. There will also be a possibility for your child to participate in the long-term extension study, after completion of the main safety and efficacy study, where they will receive Ubrogepant for a year.
Who can participate?
Your child may qualify for the study if they are between the ages of 6-17 years old, have experienced migraines for at least 6 months, and experienced between 1 and 14 migraine attacks per month.
Where is the study taking place?
The study is being conducted at our Hollywood, Weston, and Boynton offices.
Is compensation provided?

Apply for this study

Please enter your name, a valid phone number, and a valid email address where you can be contacted.

More clinical trials at Encore Medical Research